Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Stock Information for Candel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Candel Therapeutics Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Rezolute to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.